Related Experiment Video

Updated: Feb 19, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K

Antibody-drug conjugates: new drugs - new toxicities

Megan H Wong1,2, Nur Rahman3, Maryam Lustberg1

  • 1Department of Internal Medicine - Medical Oncology, Yale School of Medicine, Yale University, New Haven, Connecticut, USA.

Current Opinion in Oncology
|February 18, 2026
PubMed
Abstract

Insights

Antibody-drug conjugates (ADCs) offer targeted cancer therapy but can cause toxicities. Early recognition and management of these adverse events are crucial for patient care and quality of life.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Antibody-drug conjugates (ADCs) represent a significant advancement in solid tumor treatment.
  • ADCs utilize monoclonal antibodies for targeted delivery of cytotoxic agents.
  • The expanding use of ADCs necessitates a thorough understanding of their safety profiles.

Purpose of the Study:

  • To review the toxicity profiles of currently available ADCs for solid tumors.
  • To outline practical strategies for monitoring and managing treatment-related adverse events.
  • To emphasize the importance of proactive toxicity mitigation in clinical practice.

Main Methods:

  • Comprehensive literature review of ADCs in solid tumor treatment.
  • Analysis of reported toxicities associated with ADC therapy.
  • Synthesis of current guidelines and expert recommendations for toxicity management.

Main Results:

  • ADCs are associated with a wide range of acute and chronic toxicities.
  • Toxicities stem from off-target payload effects, antibody components, and linker instability.
  • Both common and serious treatment-related toxicities have been documented, requiring tailored management.

Conclusions:

  • Effective management of ADC-related toxicities is essential for optimizing patient outcomes.
  • Proactive toxicity monitoring and supportive care are critical for maximizing therapeutic benefits.
  • Integrating toxicity mitigation strategies enhances patient quality of life during ADC therapy.
Keywords:
antibody-drug conjugatessupportive caretoxicities

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.3K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.8K

Related Concept Videos

Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
36
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
38
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
25
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
27
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
26
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
35